No products in the cart.
Pre-made Setoxaximab benchmark antibody ( Whole mAb, anti-Shiga Toxin Type 2 therapeutic antibody) for drug discovery and mechanism of action (MOA) research
Cat:GMP-Bios-ab-516
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Setoxaximab biosimilar, Whole Mab: Anti-Shiga Toxin Type 2 therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Products Name (INN Index) | Pre-Made Setoxaximab biosimilar, Whole Mab: Anti-Shiga Toxin Type 2 therapeutic antibody |
|---|---|
| INN Name | Setoxaximab |
| Target | Shiga Toxin Type 2 |
| Format | Whole mAb |
| Derivation | Chimeric (Mouse/Human) |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2012 |
| Year Recommended | 2013 |
| Companies | Sunol Molecular Corporation,Uniformed Services University of the Health Sciences,BELLUS Health,Taro Pharmaceuticals Inc |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | Haemolytic uraemic syndrome,Shiga-toxigenic Escherichia coli infections |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | Shiga Toxin Type 2 |
| Package |
Previous slide
Next slide
